# Lindsay Corp: financial statements, quarterly

LNN · NYSE · CIK 836157 · [Industrials](/sectors/industrials.md) · fiscal year ends Aug 31

Pages: [Overview](/companies/lnn.md) · [Financials](/companies/lnn/financials.md) · [Filings](/companies/lnn/filings.md) · [Insiders](/companies/lnn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lnn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | Q4 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [154](/filings/0000950170-25-002840.md) | [147](/filings/0000950170-25-050389.md) | [134](/filings/0000950170-25-090392.md) | [149 d](/filings/0001193125-26-428926.md) | [161](/filings/0001193125-26-007695.md) | [184](/filings/0001193125-26-140093.md) | [166](/filings/0001193125-26-294516.md) | [149 d](/filings/0001193125-26-428926.md) | [151](/filings/0001193125-26-007695.md) | [155](/filings/0001193125-26-140093.md) | [157](/filings/0001193125-26-294516.md) | [158 d](/filings/0001193125-26-428926.md) |
| Cost of revenue | $m | [111](/filings/0000950170-25-002840.md) | [103](/filings/0000950170-25-050389.md) | [92.7](/filings/0000950170-25-090392.md) | [109 d](/filings/0001193125-26-428926.md) | [116](/filings/0001193125-26-007695.md) | [125](/filings/0001193125-26-140093.md) | [116](/filings/0001193125-26-294516.md) | [109 d](/filings/0001193125-26-428926.md) | [106](/filings/0001193125-26-007695.md) | [115](/filings/0001193125-26-140093.md) | [113](/filings/0001193125-26-294516.md) | [118 d](/filings/0001193125-26-428926.md) |
| Gross profit | $m | [49.9](/filings/0000950170-25-002840.md) | [49.0](/filings/0000950170-25-050389.md) | [46.5](/filings/0000950170-25-090392.md) | [45.7 d](/filings/0001193125-26-428926.md) | [50.0](/filings/0001193125-26-007695.md) | [62.5](/filings/0001193125-26-140093.md) | [53.6](/filings/0001193125-26-294516.md) | [44.7 d](/filings/0001193125-26-428926.md) | [50.1](/filings/0001193125-26-007695.md) | [42.3](/filings/0001193125-26-140093.md) | [47.8](/filings/0001193125-26-294516.md) | [43.5 d](/filings/0001193125-26-428926.md) |
| Research and development | $m | [4.4](/filings/0000950170-25-002840.md) | [3.9](/filings/0000950170-25-050389.md) | [4.3](/filings/0000950170-25-090392.md) | [4.6 d](/filings/0001193125-26-428926.md) | [3.9](/filings/0001193125-26-007695.md) | [4.2](/filings/0001193125-26-140093.md) | [4.7](/filings/0001193125-26-294516.md) | [5.2 d](/filings/0001193125-26-428926.md) | [4.6](/filings/0001193125-26-007695.md) | [4.1](/filings/0001193125-26-140093.md) | [4.7](/filings/0001193125-26-294516.md) | [3.6 d](/filings/0001193125-26-428926.md) |
| Operating income | $m | [21.1](/filings/0000950170-25-002840.md) | [22.1](/filings/0000950170-25-050389.md) | [19.9](/filings/0000950170-25-090392.md) | [13.5 d](/filings/0001193125-26-428926.md) | [20.9](/filings/0001193125-26-007695.md) | [32.1](/filings/0001193125-26-140093.md) | [23.8](/filings/0001193125-26-294516.md) | [11.3 d](/filings/0001193125-26-428926.md) | [19.6](/filings/0001193125-26-007695.md) | [13.0](/filings/0001193125-26-140093.md) | [18.5](/filings/0001193125-26-294516.md) | [15.8 d](/filings/0001193125-26-428926.md) |
| Interest expense | $m | [0.9](/filings/0000950170-24-001854.md) | [0.8](/filings/0000950170-24-041804.md) | [0.8](/filings/0000950170-24-078449.md) | [0.8 d](/filings/0001193125-25-248751.md) | [0.8](/filings/0000950170-25-002840.md) | [0.4](/filings/0000950170-25-050389.md) | [0.3](/filings/0000950170-25-090392.md) | [0.3 d](/filings/0001193125-25-248751.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | [6.0](/filings/0000950170-25-002840.md) | [4.6](/filings/0000950170-25-050389.md) | [(0.2)](/filings/0000950170-25-090392.md) | [2.4 d](/filings/0001193125-26-428926.md) | [4.9](/filings/0001193125-26-007695.md) | [6.6](/filings/0001193125-26-140093.md) | [6.2](/filings/0001193125-26-294516.md) | [2.8 d](/filings/0001193125-26-428926.md) | [5.4](/filings/0001193125-26-007695.md) | [3.5](/filings/0001193125-26-140093.md) | [4.8](/filings/0001193125-26-294516.md) | [6.0 d](/filings/0001193125-26-428926.md) |
| Net income | $m | [15.0](/filings/0000950170-25-002840.md) | [18.1](/filings/0000950170-25-050389.md) | [20.4](/filings/0000950170-25-090392.md) | [12.7 d](/filings/0001193125-26-428926.md) | [17.2](/filings/0001193125-26-007695.md) | [26.6](/filings/0001193125-26-140093.md) | [19.5](/filings/0001193125-26-294516.md) | [10.8 d](/filings/0001193125-26-428926.md) | [16.5](/filings/0001193125-26-007695.md) | [12.0](/filings/0001193125-26-140093.md) | [15.8](/filings/0001193125-26-294516.md) | [11.3 d](/filings/0001193125-26-428926.md) |
| Diluted EPS | $ per share | [1.36](/filings/0000950170-25-002840.md) | [1.64](/filings/0000950170-25-050389.md) | [1.85](/filings/0000950170-25-090392.md) | not reported | [1.57](/filings/0001193125-26-007695.md) | [2.44](/filings/0001193125-26-140093.md) | [1.78](/filings/0001193125-26-294516.md) | not reported | [1.54](/filings/0001193125-26-007695.md) | [1.15](/filings/0001193125-26-140093.md) | [1.53](/filings/0001193125-26-294516.md) | not reported |
| Basic EPS | $ per share | [1.36](/filings/0000950170-25-002840.md) | [1.64](/filings/0000950170-25-050389.md) | [1.85](/filings/0000950170-25-090392.md) | not reported | [1.58](/filings/0001193125-26-007695.md) | [2.45](/filings/0001193125-26-140093.md) | [1.80](/filings/0001193125-26-294516.md) | not reported | [1.55](/filings/0001193125-26-007695.md) | [1.15](/filings/0001193125-26-140093.md) | [1.54](/filings/0001193125-26-294516.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [159](/filings/0000950170-25-002840.md) | [133](/filings/0000950170-25-050389.md) | [140](/filings/0000950170-25-090392.md) | [191](/filings/0001193125-25-248751.md) | [194](/filings/0001193125-26-007695.md) | [172](/filings/0001193125-26-140093.md) | [196](/filings/0001193125-26-294516.md) | [251](/filings/0001193125-26-428926.md) | [200](/filings/0001193125-26-007695.md) | [186](/filings/0001193125-26-140093.md) | [155](/filings/0001193125-26-294516.md) | [190](/filings/0001193125-26-428926.md) |
| Current assets | $m | [501](/filings/0000950170-25-002840.md) | [501](/filings/0000950170-25-050389.md) | [489](/filings/0000950170-25-090392.md) | [493](/filings/0001193125-25-248751.md) | [502](/filings/0001193125-26-007695.md) | [527](/filings/0001193125-26-140093.md) | [547](/filings/0001193125-26-294516.md) | [533](/filings/0001193125-26-428926.md) | [507](/filings/0001193125-26-007695.md) | [499](/filings/0001193125-26-140093.md) | [480](/filings/0001193125-26-294516.md) | [472](/filings/0001193125-26-428926.md) |
| Total assets | $m | [764](/filings/0000950170-25-002840.md) | [765](/filings/0000950170-25-050389.md) | [758](/filings/0000950170-25-090392.md) | [760](/filings/0001193125-25-248751.md) | [771](/filings/0001193125-26-007695.md) | [814](/filings/0001193125-26-140093.md) | [841](/filings/0001193125-26-294516.md) | [841](/filings/0001193125-26-428926.md) | [828](/filings/0001193125-26-007695.md) | [838](/filings/0001193125-26-140093.md) | [822](/filings/0001193125-26-294516.md) | [815](/filings/0001193125-26-428926.md) |
| Current liabilities | $m | [142](/filings/0000950170-25-002840.md) | [129](/filings/0000950170-25-050389.md) | [124](/filings/0000950170-25-090392.md) | [126](/filings/0001193125-25-248751.md) | [130](/filings/0001193125-26-007695.md) | [145](/filings/0001193125-26-140093.md) | [150](/filings/0001193125-26-294516.md) | [144](/filings/0001193125-26-428926.md) | [148](/filings/0001193125-26-007695.md) | [165](/filings/0001193125-26-140093.md) | [164](/filings/0001193125-26-294516.md) | [150](/filings/0001193125-26-428926.md) |
| Total liabilities | $m | [297](/filings/0000950170-25-002840.md) | [282](/filings/0000950170-25-050389.md) | [278](/filings/0000950170-25-090392.md) | [279](/filings/0001193125-25-248751.md) | [283](/filings/0001193125-26-007695.md) | [298](/filings/0001193125-26-140093.md) | [312](/filings/0001193125-26-294516.md) | [308](/filings/0001193125-26-428926.md) | [310](/filings/0001193125-26-007695.md) | [330](/filings/0001193125-26-140093.md) | [323](/filings/0001193125-26-294516.md) | [309](/filings/0001193125-26-428926.md) |
| Long-term debt | $m | [115](/filings/0000950170-25-002840.md) | [115](/filings/0000950170-25-050389.md) | [115](/filings/0000950170-25-090392.md) | [115](/filings/0001193125-25-248751.md) | [115](/filings/0001193125-26-007695.md) | [115](/filings/0001193125-26-140093.md) | [115](/filings/0001193125-26-294516.md) | [115](/filings/0001193125-26-428926.md) | [115](/filings/0001193125-26-007695.md) | [115](/filings/0001193125-26-140093.md) | [115](/filings/0001193125-26-294516.md) | [115](/filings/0001193125-26-428926.md) |
| Current portion of debt | $m | [0.2](/filings/0000950170-25-002840.md) | [0.2](/filings/0000950170-25-050389.md) | [0.2](/filings/0000950170-25-090392.md) | [0.2](/filings/0001193125-25-248751.md) | [0.2](/filings/0001193125-26-007695.md) | [0.2](/filings/0001193125-26-140093.md) | [0.2](/filings/0001193125-26-294516.md) | [0.2](/filings/0001193125-26-428926.md) | [0.2](/filings/0001193125-26-007695.md) | [0.1](/filings/0001193125-26-140093.md) | [0.1](/filings/0001193125-26-294516.md) | [0.0](/filings/0001193125-26-428926.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [467](/filings/0000950170-25-050389.md) | [483](/filings/0000950170-25-090392.md) | [480](/filings/0000950170-25-090392.md) | [481](/filings/0001193125-26-428926.md) | [488](/filings/0001193125-26-140093.md) | [516](/filings/0001193125-26-294516.md) | [529](/filings/0001193125-26-294516.md) | [533](/filings/0001193125-26-428926.md) | [518](/filings/0001193125-26-140093.md) | [508](/filings/0001193125-26-294516.md) | [499](/filings/0001193125-26-294516.md) | [506](/filings/0001193125-26-428926.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q4 FY2024 (2024-08-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q4 FY2025 (2025-08-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) | Q4 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [21.9](/filings/0000950170-25-002840.md) | [(9.7) d](/filings/0000950170-25-050389.md) | [30.5 d](/filings/0000950170-25-090392.md) | [53.1 d](/filings/0001193125-26-428926.md) | [21.6](/filings/0001193125-26-007695.md) | [12.3 d](/filings/0001193125-26-140093.md) | [35.0 d](/filings/0001193125-26-294516.md) | [64.0 d](/filings/0001193125-26-428926.md) | [(0.6)](/filings/0001193125-26-007695.md) | [24.6 d](/filings/0001193125-26-140093.md) | [6.7 d](/filings/0001193125-26-294516.md) | [44.3 d](/filings/0001193125-26-428926.md) |
| Capital expenditure | $m | [6.9](/filings/0000950170-25-002840.md) | [11.8 d](/filings/0000950170-25-050389.md) | [4.8 d](/filings/0000950170-25-090392.md) | [5.5 d](/filings/0001193125-26-428926.md) | [9.1](/filings/0001193125-26-007695.md) | [9.8 d](/filings/0001193125-26-140093.md) | [9.3 d](/filings/0001193125-26-294516.md) | [14.2 d](/filings/0001193125-26-428926.md) | [14.5](/filings/0001193125-26-007695.md) | [13.0 d](/filings/0001193125-26-140093.md) | [8.1 d](/filings/0001193125-26-294516.md) | [4.7 d](/filings/0001193125-26-428926.md) |
| Dividends paid | $m | [3.9](/filings/0000950170-25-002840.md) | [3.9 d](/filings/0000950170-25-050389.md) | [3.8 d](/filings/0000950170-25-090392.md) | [3.9 d](/filings/0001193125-26-428926.md) | [3.9](/filings/0001193125-26-007695.md) | [3.9 d](/filings/0001193125-26-140093.md) | [3.9 d](/filings/0001193125-26-294516.md) | [4.0 d](/filings/0001193125-26-428926.md) | [3.9](/filings/0001193125-26-007695.md) | [3.8 d](/filings/0001193125-26-140093.md) | [3.8 d](/filings/0001193125-26-294516.md) | [3.9 d](/filings/0001193125-26-428926.md) |
| Share repurchases | $m | not reported | not reported | [17.9 d](/filings/0000950170-25-090392.md) | [4.6 d](/filings/0001193125-26-428926.md) | [0.0](/filings/0001193125-26-007695.md) | [1.4 d](/filings/0001193125-26-140093.md) | [1.2 d](/filings/0001193125-26-294516.md) | [8.9 d](/filings/0001193125-26-428926.md) | [30.3](/filings/0001193125-26-007695.md) | [25.2 d](/filings/0001193125-26-140093.md) | [25.2 d](/filings/0001193125-26-294516.md) | [0.0 d](/filings/0001193125-26-428926.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-11-30) | Q2 FY2023 (2023-02-28) | Q3 FY2023 (2023-05-31) | Q1 FY2024 (2023-11-30) | Q2 FY2024 (2024-02-29) | Q3 FY2024 (2024-05-31) | Q1 FY2025 (2024-11-30) | Q2 FY2025 (2025-02-28) | Q3 FY2025 (2025-05-31) | Q1 FY2026 (2025-11-30) | Q2 FY2026 (2026-02-28) | Q3 FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.1](/filings/0000950170-24-001854.md) | [11.1](/filings/0000950170-24-041804.md) | [11.1](/filings/0000950170-24-078449.md) | [11.1](/filings/0000950170-25-002840.md) | [11.1](/filings/0000950170-25-050389.md) | [11.0](/filings/0000950170-25-090392.md) | [10.9](/filings/0001193125-26-007695.md) | [10.9](/filings/0001193125-26-140093.md) | [10.9](/filings/0001193125-26-294516.md) | [10.7](/filings/0001193125-26-007695.md) | [10.5](/filings/0001193125-26-140093.md) | [10.3](/filings/0001193125-26-294516.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,169,930 at 2026-10-21, from the cover of the [10-K filed 2026-10-22](/filings/0001193125-26-428926.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.